Skip to main content
. 2008 Dec 18;100(2):195–199. doi: 10.1111/j.1349-7006.2008.01022.x

Figure 3.

Figure 3

Five‐year survival rate according to the preoperative serum tumor markers carcinoembryonic antigen (preCEA) or CA19‐9 (preCA19‐9) in subgroups (stage III or stage IV) of colorectal cancer between 2001 and 2004. (a) preCEA is no longer of a prognostic relevance in stage III colorectal cancer, whereas patients with elevated preCEA showed significantly poorer prognosis than those with normal preCEA.( 20 ) (b) In stage IV colorectal patients, cases with elevated preCA19‐9 showed significantly poorer prognosis than those with normal preCA19‐9 (P < 0.0001).